Table 3.
Main derived-endothelial factors involved in hemostasis and their dynamics during normal pregnancy.
| Prothrombotic factors | Function | Dynamic in healthy pregnancy | Antithrombotic factors | Function | Dynamic in healthy pregnancy | |
|---|---|---|---|---|---|---|
| Primary hemostasis | vWF | Platelets aggregation, FVIII transport | ↑ | ADAMTS-13 | Cleavage of vWF multimers | ↓ |
| TXA2 | Platelets aggregation, vasoconstriction | ↓ | NO | Inhibition of platelets activation, vasorelaxation, anti-inflammatory properties | ↑ | |
| PAF | Platelets aggregation, vasoconstriction | No data | PGI2 | Inhibition of platelets activation, vasorelaxation | ↑ | |
| Coagulation | Tissue factor | Binding to FVII, initiation of blood coagulation (extrinsic pathway) | ↑ | TPFI/TFPI-2 | Inhibition of coagulation by binding to TF, factors Va, and Xa | →/↑ |
| PARs | Thrombin receptors | No data | TM | Formation of a thrombin complex enhancing protein C affinity | ↑ | |
| Heparan-sulfate | Binding to antithrombin | Few data, glycocalyx thinning | ||||
| Fibrinolysis | PAI-1 | Fibrinolysis inhibitor | ↑ | t-PA | Fibrinolysis activator | ↑ |
NO, nitric oxide; PAI-1, plasminogen activator inhibitor type 1; PAF, platelet activating factor; PARs, protease activated receptor; PGI2, prostacyclin I2; t-PA, tissue plasminogen activator; TFPI, tissue factor pathway inhibitor; TM, thrombomodulin; TXA2, thromboxane A2; vWF, von Willebrand factor.